Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) tinted gains of +4.27% (+0.85 points) to US$20.75. The volume of 0.91 Million shares climbed down over an trading activity of 1.39 Million shares. EPS ratio determined by looking at last 12 month figures is -0.72. Over the same time span, the stock marked US$20.74 as its best level and the lowest price reached was US$12.89. The corporation has a market cap of US$3.05 Billion.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s earnings per share has been growing at a -2.8 percent rate over the past 5 year when average revenue increase was noted as 14.7 percent. The return on equity ratio or ROE stands at 0 percent while most common profitability ratio return on investment (ROI) was -19.4 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of -34.1 percent and possesses 93.3 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 3 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 4 think it is Hold. Recently, analysts have updated the overall rating to 2.42. 3 analysts recommended Overweight these shares while 2 recommended Underweight, according to FactSet data. Ltd. (NASDAQ:WIX) is worth US$5.09 Billion and has recently risen 4.27% to US$108.65. The latest exchange of 0.6 Million shares is below its average trading activity of 604.4 Million shares. The day began at US$103.75 but the price moved to US$103.75 at one point during the trading and finally capitulating to a session high of US$108.75. The stock tapped a 52-week high of US$109.2 while the mean 12-month price target for the shares is US$100.33.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 144.87, and a price to sales ratio of 10.8. For the past 5 years, the company’s revenue has grown 57.7%, while the company’s earnings per share has grown -18.1%. With an institutional ownership near 0%, it carries an earnings per share ratio of -1.16.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 6 brokerage firms polled by Factset Research. At present, 3 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 7 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.81.